All questions
Safety: Otezla (apremilast) in plaque psoriasis
9 questions · 8 sources
Safety questions that apply to every indication of Otezla are on Otezla (apremilast), all indications: Safety.
Side effects
What are the most common side effects of Otezla for plaque psoriasis?
Applies to Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy (ESTEEM 1 and ESTEEM 2; PSOR-1 and PSOR-2 in the label)
Note: Table 4 columns are placebo (N = 506) and OTEZLA 30 mg twice daily (N = 920), each as number (%) of subjects through Week 16.
What side effects did Otezla cause in mild to moderate plaque psoriasis (ADVANCE)?
Applies to Mild to moderate plaque psoriasis in adults with an inadequate response or intolerance to topical therapy (ADVANCE; PSOR-4 in the label)
Note: The ADVANCE adverse event rates are shown in an image on the safety page and are not quoted.
What are the side effects of Otezla in children with plaque psoriasis?
Applies to Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy and weigh at least 20 kg (OTEZLA) or at least 50 kg (OTEZLA XR)
Note: The SPROUT adverse event rates are shown in an image on the pediatric safety page and are not quoted.
What side effects did Otezla cause in scalp psoriasis (STYLE)?
Applies to Moderate to severe plaque psoriasis of the scalp in adults (STYLE; PSOR-3 in the label)
Note: The Prescribing Information names the trial PSOR-3; the Otezla HCP site names it STYLE.
What are the long-term side effects of Otezla through 5 years (ESTEEM)?
Applies to Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy (ESTEEM 1 and ESTEEM 2; PSOR-1 and PSOR-2 in the label)
Note: The adverse reaction rates through week 260 are shown in an image on the safety page and are not quoted. The open-label extension caveat accompanies the ESTEEM 1 PASI-75 results through week 260 on the PASI-75 efficacy page; it states that the extension (weeks 52 to 260) was not blinded or controlled.
Safety
Did Otezla increase serious infections or MACE vs placebo at 16 weeks (ESTEEM)?
Applies to Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy (ESTEEM 1 and ESTEEM 2; PSOR-1 and PSOR-2 in the label)
Note: The comparison with placebo covers the 16-week placebo-controlled period of ESTEEM 1 and ESTEEM 2; the incidence rates through week 16 and through 5 years are shown in an image on the safety page and are not quoted. MACE is major adverse cardiovascular events.
Warnings
Does Otezla cause weight loss?
Monitoring
Does Otezla require lab monitoring?
Note: The Prescribing Information recommends regular weight monitoring, and close monitoring of growth in pediatric patients.
Does Otezla require TB testing before treatment starts?
Note: The second passage is a selected exclusion criterion of the ESTEEM trials, from the ESTEEM study design page.